Adenomyosis uteri seen during laparoscopy
|Classification and external resources|
Adenomyosis (pronounced A - den - oh - my - oh - sis) is a medical condition characterized by the presence of ectopic glandular tissue found in muscle. The term adenomyosis is derived from the Greek terms adeno- (meaning gland), myo- (meaning muscle), and -osis (meaning condition). Previously named as endometriosis interna, adenomyosis differs from endometriosis and these two diseases are found together in 10% of the cases.
It usually refers to ectopic endometrial tissue (the inner lining of the uterus) within the myometrium (the thick, muscular layer of the uterus). The term "adenomyometritis" specifically implies involvement of the uterus.
The condition is typically found in women between the ages of 35 and 50. Patients with adenomyosis can have painful and/or profuse menses (dysmenorrhea & menorrhagia, respectively). However, because the endometrial glands can be trapped in the myometrium, it is possible to have increased pain without increased blood. (This can be used to distinguish adenomyosis from endometrial hyperplasia; in the latter condition, increased bleeding is more common.)
In adenomyosis, basal endometrium penetrates into hyperplastic myometrial fibers. Therefore, unlike functional layer, basal layer does not undergo typical cyclic changes with menstrual cycle.
Adenomyosis may involve the uterus focally, creating an adenomyoma. With diffuse involvement, the uterus becomes bulky and heavier.
Signs and symptoms
Some women with adenomyosis do not experience any symptoms, while others may have severe, debilitating symptoms. The endometrial implants that grow into the wall of the uterus bleed during menstruation (the same as endometrial tissue bleeds) and are discharged vaginally as menstrual bleeding. The vaginal pressure can be severe enough to feel like the uterus is trying to push out through the vagina, like the first stage of labor when the baby's head pushes into the cervix. Other symptoms include;
- Intense debilitating pain all the time and/or
- Acute & increasing pain at menstruation and ovulation
- Strong 'contraction' feel of uterus
- Abdominal cramps
- A 'bearing' down feeling
- Pressure on bladder
- Dragging sensation down thighs and legs
- Heavy bleeding and flooding
- Large blood clots
- Prolonged bleeding i.e.; up to 8–14 days
Adenomyosis itself can cause infertility issues, however chances for fertility can be improved if the adenomyosis has resolved following hormone therapies like levonorgestrel therapy. The discontinuation of medication or removal of IUD can be timed to be coordinated with fertility treatments. There has also been one report of successful pregnancy and healthy birth following high frequency ultrasound ablation of adenomyosis.
Adenomyosis is associated with an increased incidence of preterm labour and premature rupture of membranes. Women with adenomyosis are at an increased risk of anemia. This can cause fatigue, dizziness, and moodiness. Adenomyosis has also been linked with anxiety, depression, and irritability.
The cause of adenomyosis is unknown, although it has been associated with any sort of uterine trauma that may break the barrier between the endometrium and myometrium, such as a caesarean section, tubal ligation, pregnancy termination, and any pregnancy. It can be linked with endometriosis, but studies looking into similarities and differences between these two conditions have conflicting results.
Some say that the reason adenomyosis is common in women between the ages of 35 and 50 is because it is between these ages that women have an excess of estrogen (Estrogen Dominance). Near the age of 35, women typically cease to create as much natural progesterone, which counters the effects of estrogen. After the age of 50, due to menopause, women do not create as much estrogen.
Adenomyosis correlates with abnormal amounts of multiple substances, possibly indicating a causative link in its pathogenesis, although correlation does not imply causation:
- Endometrial IL-18 receptor mRNA and the ratio of IL-18 binding protein to IL-18 are significantly increased in adenomyosis patients in comparison to normal people.
- Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of women with adenomyosis during the implantation window.
The uterus may be imaged using ultrasound (US) or magnetic resonance imaging (MRI). Transvaginal ultrasound is the most cost effective and most available method. Either modality may show an enlarged uterus. Among the transvaginal ultrasound diagnostic findings of adenomyosis, the presence of subendometrial linear striations has the highest diagnostic accuracy, with a specificity of 96% and a positive predictive value of 80% for adenomyosis. Other supportive findings are a globular configuration and myometrial cysts.
MRI provides better diagnostic capability due to the increased soft tissue differentiation, allowable through higher spatial and contrast resolution. MRI is limited by other factors, but not by calcified uterine fibroids (as is ultrasound). In particular, MRI is better able to differentiate adenomyosis from multiple small uterine fibroids. The uterus will have a thickened junctional zone with diminished signal on both T1 and T2 weighted sequences due to susceptibility effects of iron deposition due to chronic microhemorrhage. A thickness of the junctional zone greater than 10 to 12 mm (depending on who you read) is diagnostic of adenomyosis (<8 mm is normal). Interspersed within the thickened, hypointense signal of the junctional zone, one will often see foci of hyperintensity (brightness) on the T2 weighted scans representing small cystically dilatated glands or more acute sites of microhemorrhage.
MRI can be used to classify adenomyosis based on the depth of penetration of the ectopic endometrium into the myometrium.
Exact diagnosis of adenomyosis only possible in posthysterectomy specimen.
The differential of abnormal uterine bleeding includes
Conservative treatment often consists of anti-inflammatory medications, such as ibuprofen or other NSAIDs. Hormonal manipulation may include combined or progestin-only oral contraceptives as well as other options such as transdermal patches and progesterone-releasing intrauterine devices. Long term treatments are shifting from medications commonly used as oral contraceptives to the use of levonorgestrel releasing IUDs. Hormonal suppression may be used in the form of danazol or a gonadotropin-releasing hormone agonist. These medications simulate menopause, a period in which adenomyosis often resolves naturally.
Surgical options may include endometrial ablation, laparoscopic myometrial electrocoagulation and adenomyoma excision. These have demonstrated positive results in several studies, though long-term data is lacking. A non-surgical procedure, uterine artery embolization may also be used to block the blood supply to the ectopic endometrium, selectively killing the problematic tissue. High frequency ultrasound surgical ablation is also being explored as a treatment for both focal and diffuse forms of adenomyosis over complete hysterectomy.Hysterectomy may be warranted in some cases where fertility is not desired, and all other treatments have failed.
It is advocated that adenomyosis poses no increased risk for cancer development. However, both entities could coexist and the endometrial tissue within the myometrium could harbor endometrial adenocarcinoma, with potentially deep myometrial invasion. As the condition is estrogen-dependent, menopause presents a natural cure. Patients with adenomyosis often also have leiomyomata and/or endometriosis.
- "adenomyosis" at Dorland's Medical Dictionary
- Katz VL (2007). Comprehensive gynecology (5th ed.). Philadelphia PA: Mosby Elsevier.
- "adenomyometritis" at Dorland's Medical Dictionary
- Matalliotakis, I.; Kourtis, A.; Panidis, D. (2003). "Adenomyosis". Obstetrics and gynecology clinics of North America 30 (1): 63–82, viii. doi:10.1016/S0889-8545(02)00053-0. PMID 12699258.
- Maheshwari, A.; Gurunath, S.; Fatima, F.; Bhattacharya, S. (2012). "Adenomyosis and subfertility: A systematic review of prevalence, diagnosis, treatment and fertility outcomes". Human Reproduction Update 18 (4): 374. doi:10.1093/humupd/dms006.
- Leyendecker G, Kunz G, Kissler S, Wildt L (August 2006). "Adenomyosis and reproduction". Best Pract Res Clin Obstet Gynaecol 20 (4): 523–46. doi:10.1016/j.bpobgyn.2006.01.008. PMID 16520094.
- Benagiano, G.; Brosens, I.; Habiba, M. (2013). "Structural and molecular features of the endomyometrium in endometriosis and adenomyosis". Human Reproduction Update 20 (3): 386–402. doi:10.1093/humupd/dmt052. ISSN 1355-4786. PMID 24140719.
- Huang, H.; Yu, H.; Chan, S.; Lee, C.; Wang, H.; Soong, Y. (2010). "Eutopic endometrial interleukin-18 system mRNA and protein expression at the level of endometrial-myometrial interface in adenomyosis patients". Fertility and Sterility 94 (1): 33–39. doi:10.1016/j.fertnstert.2009.01.132. PMID 19394601.
- Xiao, Y.; Sun, X.; Yang, X.; Zhang, J.; Xue, Q.; Cai, B.; Zhou, Y. (2010). "Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window". Fertility and Sterility 94 (1): 85–89. doi:10.1016/j.fertnstert.2009.03.012. PMID 19361790.
- Kepkep K, Tuncay YA, Göynümer G, Tutal E (2007). "Transvaginal sonography in the diagnosis of adenomyosis: which findings are most accurate?". Ultrasound Obstet Gynecol 30 (3): 341–5. doi:10.1002/uog.3985. PMID 17659649.
- Cho S, Nam A, Kim H et al. (2008). "Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis.". Am J Obstet Gynecol 198: 373.e1–373.e7. doi:10.1016/j.ajog.2007.10.798.
- , Levgur, M. (2007). "Therapeutic options for adenomyosis: a review". Archives of Gynecology and Obstetrics 276 (1): 1–15. doi:10.1007/s00404-006-02d99-8. PMID 17186255.
- Ismiil N, Rasty G, Ghorab Z et al. (August 2007). "Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion". Ann Diagn Pathol 11 (4): 252–7. doi:10.1016/j.anndiagpath.2006.08.011. PMID 17630108.